ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
General Health & Fitness
Health & Wellness
Novartis Lp(a) Drug Study
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Vince" data-source="post: 170560" data-attributes="member: 843"><p>Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With CVD (Lp(a)HORIZON)</p><p></p><p><a href="https://www.clinicaltrials.gov/ct2/show/NCT04023552" target="_blank">Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With CVD - Full Text View - ClinicalTrials.gov</a></p><p></p><ul> <li data-xf-list-type="ul"><em>Novartis announced today that it is exercising its option to license the rights to develop and commercialize TQJ230, an investigational agent previously known as AKCEA-APO(a)-LRx, from Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals, for targeted cardiovascular therapy </em><br /> </li> <li data-xf-list-type="ul"><em>Novartis is now responsible for worldwide development and commercialization of TQJ230</em><br /> </li> <li data-xf-list-type="ul"><em>Millions of people have elevated lipoprotein(a) (Lp(a)), an independent inherited cardiovascular disease (CVD) risk factor that cannot be effectively addressed by diet and other lifestyle changes</em><br /> </li> <li data-xf-list-type="ul"><em>If approved TQJ230 could be first in class treatment specifically targeting elevated Lp(a) </em></li> </ul><p><em><a href="https://www.novartis.com/news/media-releases/novartis-pursue-transformational-therapy-reduce-risk-cardiovascular-disease-people-living-elevated-levels-inherited-lipoproteina" target="_blank">Novartis to pursue transformational therapy to reduce risk of cardiovascular disease in people living with elevated levels of inherited lipoprotein(a) | Novartis</a></em></p></blockquote><p></p>
[QUOTE="Vince, post: 170560, member: 843"] Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With CVD (Lp(a)HORIZON) [URL="https://www.clinicaltrials.gov/ct2/show/NCT04023552"]Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With CVD - Full Text View - ClinicalTrials.gov[/URL] [LIST] [*][I]Novartis announced today that it is exercising its option to license the rights to develop and commercialize TQJ230, an investigational agent previously known as AKCEA-APO(a)-LRx, from Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals, for targeted cardiovascular therapy [/I] [*][I]Novartis is now responsible for worldwide development and commercialization of TQJ230[/I] [*][I]Millions of people have elevated lipoprotein(a) (Lp(a)), an independent inherited cardiovascular disease (CVD) risk factor that cannot be effectively addressed by diet and other lifestyle changes[/I] [*][I]If approved TQJ230 could be first in class treatment specifically targeting elevated Lp(a) [/I] [/LIST] [I][URL="https://www.novartis.com/news/media-releases/novartis-pursue-transformational-therapy-reduce-risk-cardiovascular-disease-people-living-elevated-levels-inherited-lipoproteina"]Novartis to pursue transformational therapy to reduce risk of cardiovascular disease in people living with elevated levels of inherited lipoprotein(a) | Novartis[/URL][/I] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
X (Twitter)
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
General Health & Fitness
Health & Wellness
Novartis Lp(a) Drug Study
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top